A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)

NCT ID: NCT06203002

Last Updated: 2025-10-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

496 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-11-29

Study Completion Date

2025-02-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Evaluation of the efficacy of LX9211 compared to placebo in reducing DPNP. Please see study website: https://diabeticpainstudy.com/

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetic Peripheral Neuropathic Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LX9211 Low Dose

LX9211 low dose, orally, once daily during a blinded treatment period.

Group Type EXPERIMENTAL

LX9211 (blinded)

Intervention Type DRUG

LX9211 (blinded) tablets

LX9211 High Dose

LX9211 high dose, orally, once daily during a blinded treatment period.

Group Type EXPERIMENTAL

LX9211 (blinded)

Intervention Type DRUG

LX9211 (blinded) tablets

LX9211 High Dose Followed by Low Dose

LX9211 high dose followed by LX9211 low dose, orally, once daily during a blinded treatment period.

Group Type EXPERIMENTAL

LX9211 (blinded)

Intervention Type DRUG

LX9211 (blinded) tablets

LX9211 Placebo

LX9211 matching placebo, orally, once daily during a blinded treatment period.

Group Type PLACEBO_COMPARATOR

Placebo (blinded)

Intervention Type DRUG

LX9211 matching placebo tablets

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Placebo (blinded)

LX9211 matching placebo tablets

Intervention Type DRUG

LX9211 (blinded)

LX9211 (blinded) tablets

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Participant has given written informed consent to participate in the study in accordance with local regulations
2. Adult male and female participants ≥18 years of age at the Screening Visit
3. Body mass index ≥18.0 to ≤40.0 kilogram per meter square (kg/m\^2) at Screening
4. Diagnosis of type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM) with chronic DPNP, at Screening
5. Pain from DPNP present for at least 6 months prior to Screening
6. At the Screening Visit, glycosylated hemoglobin (A1C) must be ≤11%.
7. Stable regimen for the treatment of T1DM or T2DM for ≥3 months prior to Screening
8. Willing to adhere to the prohibitions and restrictions specified in the protocol.

Exclusion Criteria

1. Presence of other painful conditions that may confound assessment or self-evaluation of DPNP
2. History of neurolytic or neurosurgical therapy for DPNP
3. Use of opioid medications for management of DPNP within the 2 months prior to the Screening Visit.
4. Use of prescription topical analgesics (eg, capsaicin) indicated for neuropathic pain within 3 months prior to Screening
5. Use of nonsteroidal anti-inflammatory drugs (NSAIDs) less than 2 weeks prior to Screening
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Lexicon Pharmaceuticals

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Lexicon Investigational Site (128)

Anniston, Alabama, United States

Site Status

Lexicon Investigational Site (222)

Birmingham, Alabama, United States

Site Status

Lexicon Investigational Site (189)

Daphne, Alabama, United States

Site Status

Lexicon Investigational Site (215)

Guntersville, Alabama, United States

Site Status

Lexicon Investigational Site (115)

Chandler, Arizona, United States

Site Status

Lexicon Investigational Site (195)

Phoenix, Arizona, United States

Site Status

Lexicon Investigational Site (206)

Scottsdale, Arizona, United States

Site Status

Lexicon Investigational Site (102)

Tucson, Arizona, United States

Site Status

Lexicon Investigational Site (107)

Anaheim, California, United States

Site Status

Lexicon Investigational Site (173)

Canoga Park, California, United States

Site Status

Lexicon Investigational Site (179)

Escondido, California, United States

Site Status

Lexicon Investigational Site (161)

Fresno, California, United States

Site Status

Lexicon Investigational Site (112)

Greenbrae, California, United States

Site Status

Lexicon Investigational Site (204)

Huntington Beach, California, United States

Site Status

Lexicon Investigational Site (191)

Inglewood, California, United States

Site Status

Lexicon Investigational Site (163)

Lomita, California, United States

Site Status

Lexicon Investigational Site (169)

Long Beach, California, United States

Site Status

Lexicon Investigational Site (111)

Sacramento, California, United States

Site Status

Lexicon Investigational Site (126)

Sacramento, California, United States

Site Status

Lexicon Investigational Site (129)

San Diego, California, United States

Site Status

Lexicon Investigational Site (154)

San Diego, California, United States

Site Status

Lexicon Investigational Site (124)

Tustin, California, United States

Site Status

Lexicon Investigational Site (211)

Vista, California, United States

Site Status

Lexicon Investigational Site (171)

Walnut Creek, California, United States

Site Status

Lexicon Investigational Site (181)

Walnut Creek, California, United States

Site Status

Lexicon Investigational Site (119)

Brandon, Florida, United States

Site Status

Lexicon Investigational Site (194)

Brandon, Florida, United States

Site Status

Lexicon Investigational Site (177)

Daytona Beach, Florida, United States

Site Status

Lexicon Investigational Site (198)

Fleming Island, Florida, United States

Site Status

Lexicon Investigational Site (109)

Fort Myers, Florida, United States

Site Status

Lexicon Investigational Site (180)

Hollywood, Florida, United States

Site Status

Lexicon Investigational Site (188)

Jacksonville, Florida, United States

Site Status

Lexicon Investigational Site (164)

Miami, Florida, United States

Site Status

Lexicon Investigational Site (105)

New Port Richey, Florida, United States

Site Status

Lexicon Investigational Site (146)

Orlando, Florida, United States

Site Status

Lexicon Investigational Site (144)

Orlando, Florida, United States

Site Status

Lexicon Investigational Site (123)

Ormond Beach, Florida, United States

Site Status

Lexicon Investigational Site (182)

Plantation, Florida, United States

Site Status

Lexicon Investigational Site (133)

The Villages, Florida, United States

Site Status

Lexicon Investigational Site (138)

The Villages, Florida, United States

Site Status

Lexicon Investigational Site (131)

Winter Haven, Florida, United States

Site Status

Lexicon Investigational Site (103)

Winter Park, Florida, United States

Site Status

Lexicon Investigational Site (150)

Atlanta, Georgia, United States

Site Status

Lexicon Investigational Site (151)

Marietta, Georgia, United States

Site Status

Lexicon Investigational Site (172)

Chicago, Illinois, United States

Site Status

Lexicon Investigational Site (132)

Flossmoor, Illinois, United States

Site Status

Lexicon Investigational Site (185)

El Dorado, Kansas, United States

Site Status

Lexicon Investigational Site (178)

Newton, Kansas, United States

Site Status

Lexicon Investigational Site (186)

Wichita, Kansas, United States

Site Status

Lexicon Investigational Site (213)

Owensboro, Kentucky, United States

Site Status

Lexicon Investigational Site (170)

New Orleans, Louisiana, United States

Site Status

Lexicon Investigational Site (190)

New Orleans, Louisiana, United States

Site Status

Lexicon Investigational Site (121)

Boston, Massachusetts, United States

Site Status

Lexicon Investigational Site (140)

New Bedford, Massachusetts, United States

Site Status

Lexicon Investigational Site (225)

Waltham, Massachusetts, United States

Site Status

Lexicon Investigational Site (125)

Ann Arbor, Michigan, United States

Site Status

Lexicon Investigational Site (108)

Dearborn, Michigan, United States

Site Status

Lexicon Investigational Site (139)

Olive Branch, Mississippi, United States

Site Status

Lexicon Investigational Site (104)

Hazelwood, Missouri, United States

Site Status

Lexicon Investigational Site (174)

Kansas City, Missouri, United States

Site Status

Lexicon Investigational Site (184)

Springfield, Missouri, United States

Site Status

Lexicon Investigational Site (156)

St Louis, Missouri, United States

Site Status

Lexicon Investigational Site (116)

Papillion, Nebraska, United States

Site Status

Lexicon Investigational Site (216)

Las Vegas, Nevada, United States

Site Status

Lexicon Investigational Site (162)

Las Vegas, Nevada, United States

Site Status

Lexicon Investigational Site (142)

New York, New York, United States

Site Status

Lexicon Investigational Site (227)

Rochester, New York, United States

Site Status

Lexicon Investigational Site (167)

Schenectady, New York, United States

Site Status

Lexicon Investigational Site (122)

Westfield, New York, United States

Site Status

Lexicon Investigational Site (110)

Williamsville, New York, United States

Site Status

Lexicon Investigational Site (200)

Asheville, North Carolina, United States

Site Status

Lexicon Investigational Site (209)

Greensboro, North Carolina, United States

Site Status

Lexicon Investigational Site (212)

Monroe, North Carolina, United States

Site Status

Lexicon Investigational Site (106)

Morehead City, North Carolina, United States

Site Status

Lexicon Investigational Site (145)

Winston-Salem, North Carolina, United States

Site Status

Lexicon Investigational Site (220)

Beavercreek, Ohio, United States

Site Status

Lexicon Investigational Site (168)

Dayton, Ohio, United States

Site Status

Lexicon Investigational Site (148)

Norman, Oklahoma, United States

Site Status

Lexicon Investigational Site (210)

Oklahoma City, Oklahoma, United States

Site Status

Lexicon Investigational Site (187)

Eugene, Oregon, United States

Site Status

Lexicon Investigational Site (183)

Charleston, South Carolina, United States

Site Status

Lexicon Investigational Site (201)

Columbia, South Carolina, United States

Site Status

Lexicon Investigational Site (113)

Greenville, South Carolina, United States

Site Status

Lexicon Investigational Site (205)

North Charleston, South Carolina, United States

Site Status

Lexicon Investigational Site (202)

Rock Hill, South Carolina, United States

Site Status

Lexicon Investigational Site (157)

Summerville, South Carolina, United States

Site Status

Lexicon Investigational Site (160)

Memphis, Tennessee, United States

Site Status

Lexicon Investigational Site (192)

Austin, Texas, United States

Site Status

Lexicon Investigational Site (199)

Baytown, Texas, United States

Site Status

Lexicon Investigational Site (193)

Dallas, Texas, United States

Site Status

Lexicon Investigational Site (158)

Dallas, Texas, United States

Site Status

Lexicon Investigational Site (153)

Euless, Texas, United States

Site Status

Lexicon Investigational Site (114)

Flower Mound, Texas, United States

Site Status

Lexicon Investigational Site (196)

Harlingen, Texas, United States

Site Status

Lexicon Investigational Site (120)

Houston, Texas, United States

Site Status

Lexicon Investigational Site (197)

Houston, Texas, United States

Site Status

Lexicon Investigational Site (152)

Houston, Texas, United States

Site Status

Lexicon Investigational Site (214)

Katy, Texas, United States

Site Status

Lexicon Investigational Site (155)

Lewisville, Texas, United States

Site Status

Lexicon Investigational Site (223)

Mesquite, Texas, United States

Site Status

Lexicon Investigational Site (203)

San Antonio, Texas, United States

Site Status

Lexicon Investigational Site (159)

San Antonio, Texas, United States

Site Status

Lexicon Investigational Site (221)

San Antonio, Texas, United States

Site Status

Lexicon Investigational Site (101)

Salt Lake City, Utah, United States

Site Status

Lexicon Investigational Site (219)

Salt Lake City, Utah, United States

Site Status

Lexicon Investigational Site (224)

St. George, Utah, United States

Site Status

Lexicon Investigational Site (130)

Manassas, Virginia, United States

Site Status

Lexicon Investigational Site (165)

Norfolk, Virginia, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

LX9211.204-DPN

Identifier Type: OTHER

Identifier Source: secondary_id

LX9211.1-204-DPN

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

BMS-741672 for Diabetic Neuropathic Pain
NCT00683423 COMPLETED PHASE2